CTLA4 and neoplasm: In addition, we deeply analyzed the potential value of this signature as a biomarker of tumor immunotherapy response and found that low-risk patients were more likely to benefit from postoperative chemotherapy, and they also might be benefit from ICI therapy based on anti-CTLA-4 or anti-TIM-3.